Emerging Biomarkers in Glioblastoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2013 Nov 9

PMID 24202336

Citations 45

Authors

Mairead G McNamara

Solmaz Sahebjam

Warren P Mason

Affiliations

Soon will be listed here.

Abstract

Glioblastoma, the most common primary brain tumor, has few available therapies providing significant improvement in survival. Molecular signatures associated with tumor aggressiveness as well as with disease progression and their relation to differences in signaling pathways implicated in gliomagenesis have recently been described. A number of biomarkers which have potential in diagnosis, prognosis and prediction of response to therapy have been identified and along with imaging modalities could contribute to the clinical management of GBM. Molecular biomarkers including O(6)-methlyguanine-DNA-methyltransferase (MGMT) promoter and deoxyribonucleic acid (DNA) methylation, loss of heterozygosity (LOH) of chromosomes 1p and 19q, loss of heterozygosity 10q, isocitrate dehydrogenase (IDH) mutations, epidermal growth factor receptor (EGFR), epidermal growth factor, latrophilin, and 7 transmembrane domain-containing protein 1 on chromosome 1 (ELTD1), vascular endothelial growth factor (VEGF), tumor suppressor protein p53, phosphatase and tensin homolog (PTEN), p16INK4a gene, cytochrome c oxidase (CcO), phospholipid metabolites, telomerase messenger expression (hTERT messenger ribonucleic acid [mRNA]), microRNAs (miRNAs), cancer stem cell markers and imaging modalities as potential biomarkers are discussed. Inclusion of emerging biomarkers in prospective clinical trials is warranted in an effort for more effective personalized therapy in the future.

Citing Articles

Predictive and Prognostic Significance of Molecular Biomarkers in Glioblastoma.

Shah S, Nag A, Sachithanandam S, Lucke-Wold B Biomedicines. 2025; 12(12.

PMID: 39767571 PMC: 11727522. DOI: 10.3390/biomedicines12122664.

Liquid biopsy: creating opportunities in brain space.

Trivedi R, Bhat K Br J Cancer. 2023; 129(11):1727-1746.

PMID: 37752289 PMC: 10667495. DOI: 10.1038/s41416-023-02446-0.

Long non-coding RNA in glioma: novel genetic players in temozolomide resistance.

Roh J, Im M, Kang J, Youn B, Kim W Anim Cells Syst (Seoul). 2023; 27(1):19-28.

PMID: 36819921 PMC: 9937017. DOI: 10.1080/19768354.2023.2175497.

The diagnostic and prognostic potential of the EGFR/MUC4/MMP9 axis in glioma patients.

Quesnel A, Coles N, Polvikoski T, Karagiannis G, Angione C, Islam M Sci Rep. 2022; 12(1):19868.

PMID: 36400876 PMC: 9674618. DOI: 10.1038/s41598-022-24099-4.

Cytoskeletal Protein Palladin in Adult Gliomas Predicts Disease Incidence, Progression, and Prognosis.

Mayer O, Bugis J, Kozlova D, Leemann A, Mansur S, Peerutin I Cancers (Basel). 2022; 14(20).

PMID: 36291914 PMC: 9600953. DOI: 10.3390/cancers14205130.

References

Jain R, Poisson L, Narang J, Gutman D, Scarpace L, Hwang S . Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology. 2012; 267(1):212-20. PMC: 3606543. DOI: 10.1148/radiol.12120846. View

Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. DOI: 10.1056/NEJMoa043331. View

Polley M, Lamborn K, Chang S, Butowski N, Clarke J, Prados M . Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011; 29(31):4175-80. PMC: 3208537. DOI: 10.1200/JCO.2010.32.4343. View

Chandrasekaran S, Hollander A, Xu X, Benci J, Davis J, Dorsey J . 18F-fluorothymidine-pet imaging of glioblastoma multiforme: effects of radiation therapy on radiotracer uptake and molecular biomarker patterns. ScientificWorldJournal. 2013; 2013:796029. PMC: 3649687. DOI: 10.1155/2013/796029. View

Melguizo C, Prados J, Gonzalez B, Ortiz R, Concha A, Alvarez P . MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. J Transl Med. 2012; 10:250. PMC: 3551841. DOI: 10.1186/1479-5876-10-250. View

He J, Liu Y, Zhu T, Zhu J, DiMeco F, Vescovi A . CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol Cell Proteomics. 2011; 11(6):M111.010744. PMC: 3433900. DOI: 10.1074/mcp.M111.010744. View

Yan X, Ma L, Yi D, Yoon J, Diercks A, Foltz G . A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci U S A. 2011; 108(4):1591-6. PMC: 3029739. DOI: 10.1073/pnas.1018696108. View

Tabatabai G, Stupp R, van den Bent M, Hegi M, Tonn J, Wick W . Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol. 2010; 120(5):585-92. DOI: 10.1007/s00401-010-0750-6. View

Riemenschneider M, Jeuken J, Wesseling P, Reifenberger G . Molecular diagnostics of gliomas: state of the art. Acta Neuropathol. 2010; 120(5):567-84. PMC: 2955236. DOI: 10.1007/s00401-010-0736-4. View

10.

Pope W, Qiao X, Kim H, Lai A, Nghiemphu P, Xue X . Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012; 108(3):491-8. PMC: 3997502. DOI: 10.1007/s11060-012-0847-y. View

11.

Shervington A, Patel R, Lu C, Cruickshanks N, Lea R, Roberts G . Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma. Brain Res. 2007; 1134(1):45-52. DOI: 10.1016/j.brainres.2006.11.093. View

12.

Hegi M, Janzer R, Lambiv W, Gorlia T, Kouwenhoven M, Hartmann C . Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol. 2012; 123(6):841-52. DOI: 10.1007/s00401-011-0938-4. View

13.

KADENBACH B, Huttemann M, Arnold S, Lee I, Bender E . Mitochondrial energy metabolism is regulated via nuclear-coded subunits of cytochrome c oxidase. Free Radic Biol Med. 2000; 29(3-4):211-21. DOI: 10.1016/s0891-5849(00)00305-1. View

14.

Wooten E, Fults D, Duggirala R, Williams K, Kyritsis A, Bondy M . A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolution. Neuro Oncol. 2001; 1(3):169-76. PMC: 1920743. DOI: 10.1093/neuonc/1.3.169. View

15.

Jansen M, Yip S, Louis D . Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol. 2010; 9(7):717-26. PMC: 3079431. DOI: 10.1016/S1474-4422(10)70105-8. View

16.

Gladson C, Prayson R, Liu W . The pathobiology of glioma tumors. Annu Rev Pathol. 2009; 5:33-50. PMC: 2887670. DOI: 10.1146/annurev-pathol-121808-102109. View

17.

Hattingen E, Bahr O, Rieger J, Blasel S, Steinbach J, Pilatus U . Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy. PLoS One. 2013; 8(3):e56439. PMC: 3592858. DOI: 10.1371/journal.pone.0056439. View

18.

Chiang M, Chou P, Wang W, Sze C, Chang N . Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas. Front Oncol. 2013; 3:43. PMC: 3586680. DOI: 10.3389/fonc.2013.00043. View

19.

Cho D, Lin S, Yang W, Hsu D, Lin H, Lee H . The role of cancer stem cells (CD133(+)) in malignant gliomas. Cell Transplant. 2010; 20(1):121-5. DOI: 10.3727/096368910X532774. View

20.

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View